OPM Biosciences
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A proteomics-focused biotech using mass spectrometry and AI to discover novel biologic targets for oncology and immunology therapies.
OncologyImmunology
Technology Platform
Integrated proteomics platform combining high-resolution mass spectrometry with AI-driven computational biology to identify and validate novel therapeutic targets through systematic protein analysis.
Opportunities
Growing pharmaceutical industry investment in proteomics for drug discovery, combined with China's supportive biotech policy environment and large patient populations for clinical trials.
Risk Factors
Early-stage platform validation risk, intense competition from global proteomics companies and large pharma internal capabilities, and potential challenges in translating proteomic discoveries into clinically effective therapies.
Competitive Landscape
Competes against established proteomics companies like Seer, Nautilus Biotechnology, and SomaLogic, as well as large pharma internal proteomics efforts; differentiation hinges on proprietary computational integration and focus on therapeutic target discovery rather than pure diagnostics.